Vulvodynia Clinical Trials

Find Vulvodynia Clinical Trials Near You

Evaluation of the Effectiveness of a Four-Session Low-Intensity Focal Extracorporeal Shock Wave Therapy (LiSWT) Protocol in Women With Vulvodynia: A Retrospective Observational Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Observational
SUMMARY

Vulvodynia is a chronic vulvar pain condition that can significantly affect quality of life. Low-intensity focal extracorporeal shock wave therapy has been proposed as a non-invasive therapeutic option, but real-world data remain limited. This retrospective observational study aims to evaluate the effectiveness of a four-session focal shock wave therapy protocol in women with vulvodynia treated in routine clinical practice at a university hospital. Clinical data collected during standard care, as well as questionnaire responses, will be analyzed to assess changes in symptoms and functional outcomes following treatment.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 18
Healthy Volunteers: f
View:

• Female patients aged 18 years or older

• Clinical diagnosis of vulvodynia

• Received at least one session of low-intensity focal extracorporeal shock wave therapy in routine clinical practice

Locations
Other Locations
France
CHU Nantes- Allergy Department
RECRUITING
Nantes
Contact Information
Primary
Lisa Bruckmann
lisa.bruckmann@chu-nantes.fr
+33 2 40 16 50 58
Backup
Alexandra Poinas, PhD
alexandra.poinas@chu-nantes.fr
+33 2 53 48 28 57
Time Frame
Start Date: 2026-04-01
Estimated Completion Date: 2026-12-01
Participants
Target number of participants: 50
Treatments
Women with Vulvodynia Treated With Focal Shock Wave Therapy
Women diagnosed with vulvodynia who received a standardized four-session protocol of low-intensity focal extracorporeal shock wave therapy as part of routine clinical care at a university hospital. Data are collected retrospectively from medical records.
Related Therapeutic Areas
Sponsors
Leads: Nantes University Hospital

This content was sourced from clinicaltrials.gov